Successful treatment of recalcitrant hidradenitis suppurativa with risankizumab after failure of anti-tumour necrosis factor alpha

Abstract

Hidradenitis suppurativa (HS) is a relapsing inflammatory skin disease. The cytokines IL-1β, IL-12, IL-23, IL-17 and TNF-α are involved in the inflammatory process.

The only approved drug for the treatment of moderate-to-severe cases is adalimumab (TNF-α inhibitor). However, long-term clinical responses range only from 52-57%.

Tildrakizumab (anti-IL-23), guselkumab (anti-IL-23) and ustekinumab (anti-IL-12/23) have been successfully used in HS.

Keywords

• hidradenitis suppurativa
• risankizumab
• failure
• anti-tumour necrosis
• factor alpha